[ad_1]
San Diego, March 21, 2024 (GLOBE NEWSWIRE) — Capricorn Therapy (Nasdaq: CAPR), a biotechnology company developing transforming cell and exosome therapeutics for the treatment and prevention of rare diseases, today announced that it plans to invest in two upcoming Give a speech at a conference.
event: |
HC Wainwright 2ND Annual Cell Therapy Conference |
Promotional meeting: |
March 26, 2024 at 2:00 pm ET |
Format: |
Virtual fireside chats and one-on-one meetings |
event: |
Cantor Fitzgerald Muscular Dystrophy Symposium |
Promotional meeting: |
April 3, 2024 at 1:30 pm ET |
Format: |
Virtual Fireside Chat |
Capricor CEO Linda Marbán, Ph.D., will provide the latest progress on Capricor’s lead program for the treatment of Duchenne muscular dystrophy (DMD), CAP-1002, as well as other general scientific and corporate updates. For more information about these demonstrations, please visit the Capricor website: http://capricor.com/news/events/.
About Capricor Therapy
Capricor Therapeutics, Inc. (Nasdaq: CAPR) is a biotechnology company advancing transformed cell- and exosome-based therapies to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate CAP-1002 – an allogeneic heart-derived cell therapy. Extensive preclinical and clinical studies demonstrate that CAP-1002 has immunomodulatory, anti-fibrotic and regenerative effects specifically targeting muscular dystrophy and heart disease. CAP-1002 is currently advancing into Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD). Capricor is also leveraging the power of our exosome technology using our proprietary StealthX™ platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially Treats and prevents many diseases. At Capricor, we are committed to pushing the boundaries of possibility and creating a path to transformative treatments for those in need. For more information, visit capricor.com and follow Capricor on Facebook, Instagram and Twitter.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety and intended use of Capricor’s product candidates; the initiation, conduct, scale, timing and results of the discovery effort and clinical trials; the pace of clinical trial recruitment; information regarding regulatory filings, future studies and clinical trials plans for the trial; regulatory developments involving the product, including the ability to obtain regulatory approval or otherwise bring the product to market; manufacturing capabilities; dates for regulatory meetings; statements regarding our financial outlook; achievement of product milestones and receipts from commercial partners Ability to make milestone payments; plans regarding current and future collaborative activities and ownership of commercial rights; scope, term, validity and enforceability of intellectual property rights; future royalty streams and revenue projections; financing of recently completed offerings expectations of the intended uses and expected impact of the offering; and any other statements regarding the future expectations, beliefs, goals, plans or prospects of Capricor’s management team constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statement that is not a statement of historical fact (including statements containing: “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “goals,” ” “will”, “will” and similar expressions) should also be considered forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. For more information about these and other risks that could affect Capricor’s business, see Capricor’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on March 11, 2024. The forward-looking statements in this press release are based on information available to Capricor as of the date of this press release, and Capricor assumes no obligation to update these forward-looking statements.
Capricor has partnered with Nippon Shinyaku Co., Ltd. (U.S. subsidiary: NS Pharmaceuticals, Inc.), subject to regulatory approval. CAP-1002 is an investigational new drug and is not approved for any indication. None of Capricor’s exosome-based drug candidates have been approved for clinical studies.
For more information, please contact:
Capricorn Company Contact Information:
AJ Bergman, Chief Financial Officer
abergmann@capricor.com
858.727.1755
[ad_2]
Source link